July 25, 2024
Thank you for the opportunity to speak today. My name is Grace Drew. I am a medical student at the University of Texas Health Science Center at Houston, and today I’m speaking on behalf of the National Center for Health Research. Our nonprofit research center analyzes scientific and medical data and provides objective health information to patients, providers, and policymakers. We do not accept funding from pharmaceutical companies or any companies with financial ties to our work, and therefore we have no conflicts of interest.
We appreciate the chance to participate in FDA Advisory Committee meetings like this one, which bring together experts to examine data based on complex treatment regimens. We agree with the questions raised by FDA scientists about whether the trials conducted on durvalumab adequately address the possible benefits of perioperative treatment compared to neoadjuvant or adjuvant treatment.
We all understand the need for improved treatments for non-small cell lung cancer. Patients deserve the best possible treatments based on the best possible evidence. Obviously, overtreatment can be as problematic as undertreatment, because excessive drug dosing can cause unpleasant or dangerous adverse effects, toxicity, as well as significant financial burden to patients.
We agree that the AEGEAN trial met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in event-free survival. However, we agree with FDA scientists that the design of the AEGEAN study does not allow for a within-trial assessment of the individual contributions of durvalumab given concurrently with chemotherapy in the neoadjuvant phase compared to durvalumab given in the adjuvant phase. This is especially important because emerging data from completed trials of neoadjuvant only, adjuvant only, and perioperative immune checkpoint inhibitor regimens across other drugs in the class raise questions about the need for immune checkpoint inhibitors in both perioperative phases of therapy.
Even more important, we agree with the FDA’s concern that the AEGEAN trial indicated a nonsignificant reduction in disease-free survival in the patients that received durvalumab both before and after surgery. Since it is not statistically significant, this could have occurred by chance or could be a lasting effect of the durvalumab and platinum chemotherapy treatment before surgery. This nonsignificant finding contributes to the uncertainty about whether it is beneficial for patients to receive durvalumab both before and after surgery, rather than one or the other.
We agree with the FDA scientists that it is not appropriate to conclude that durvalumab improves disease-free or overall survival, although we also agree that the data suggest that durvalumab probably doesn’t reduce disease-free or overall survival. While the overall survival rate exceeded expectation, it was not significantly greater than the overall survival of the placebo patients, and therefore could have occurred by chance. In addition, the results may be biased because the patients in the modified resected set may have differed from the placebo group in ways that affected disease-free survival. Thus, we cannot conclude that durvalumab given both before and after surgery improved overall survival.
In conclusion, the one statistically significant benefit — event-free survival — could have been due to durvalumab given either concurrently with chemotherapy in the neoadjuvant phase or in the adjuvant phase. The other results show no statistically significant benefit in terms of disease-free or overall survival. The FDA is responsible for making a decision based on studies that are adequately designed to address the benefit of perioperative treatment as compared to neoadjuvant or adjuvant treatments. Unfortunately, better designed trials are necessary to determine the safest, most effective regimen for durvalumab therapy. Thank you.
The Oncologic Drug Advisory Committee voted unanimously (11-0) that the FDA should require clinical trials that determine the individual contributions of treatment given before and after surgery before approving drugs to be given during both periods. They did not vote on whether Imfinzi should be approved for use before and after surgery despite the lack of evidence that both times are more beneficial than one or the other.